HIV vaccine
Novel Concepts for HIV Vaccine Vector Design
... candidate HIV vaccine ...Copenhagen vaccine strain) and MVA and (ii) avipoxvirus-derived ALVAC (canarypox virus) and fowlpox ...robust vaccine-elicited cellular immune responses were ...
15
Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants
... trials. Vaccine trials were selected on the basis of the avail- ability of samples according to institutional review board approval and other constraints of the source institutions, to cover as wide a range of ...
8
Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies
... The HIV pandemic continues to take its global toll, with more than 16,000 reported infections and 8,500 deaths occur- ring ...tative HIV vaccines that will be both efficacious and econom- ...of ...
8
The aftermath of the Merck's HIV vaccine trial
... the HIV vaccine field; however, they came with no surprise within the vac- cine ...the HIV-1 infection and by previous preclinical trials in monkeys. HIV-1 infection is character- ized by an ...
6
Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design
... with HIV antigens which are identified in uninfected healthy individuals and are usually missed by standard intracel- lular assay for the measurement of Th1 cytokines ...to HIV vaccine candidates in ...
6
Strategies for an HIV vaccine
... of HIV infections also have substantial implications for AIDS vaccine devel- ...opment. HIV is transmitted both venereally and ...effective HIV vaccine must elicit both mucosal ...
7
In pursuit of an HIV vaccine: an interview with Andrew McMichael
... against HIV has been a major focus, and his group has designed and tested two candidate HIV vaccines in phase I clinical ...of HIV as the cause of AIDS, we asked Sir Andrew to give us his per- sonal ...
5
Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial
... the vaccine exerted immune pressure on the V1/V2 region, Rolland et ...from HIV-infected trial participants in the vaccine group versus the placebo group—showed genetic differences relative to the ...
14
Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
... and vaccine studies suggest that nonneutralizing antibodies (nNAb) without neutralizing activity in vitro may play an important role in protection against viral infection in ...RV144 vaccine efficacy trial, ...
14
Structural insights of CD4+ Gag epitopes and HLA DRB1*10 allele complexes
... based HIV vaccine construct .Epitope based vaccine construction using conventional methods are time consuming and expensive, thus computation method for epitope based vaccine construct ...
7
Therapeutic DNA vaccination of vertically HIV-infected children: Report of the first pediatric randomised trial (PEDVAC)
... the HIV-infected pediatric population requires medication early, daily and indefinitely ...vertically HIV-infected children have a progressively increased risk of developing triple-class virological failure ...
12
Immunotherapy with an HIV-DNA Vaccine in Children and Adults
... of HIV vaccine and microbicides (Grant ...Rec HIV-1 RT, ARP694 HIV p17/24 Clade B, ARP695 HIV-1 p17/24 Clade C, ARP698 HIV-1 UG37 gp140 Clade A, ARP699 CN54 gp140 Clade C, ARP680 ...
19
HIV 1 vaccine immunogen design strategies
... in HIV immunogen design strategies, there is currently no consensus regarding practices and standards for comparative studies that may inform which designs should advance through the vaccine pipeline from ...
11
Knowledge and attitudes towards HIV vaccines among Soweto adolescents
... future HIV vaccine trials is contingent on vaccine knowl- edge and to hypothetical trial attributes ...of HIV vaccines was very low, became unwilling to partici- pate with increased ...
5
Challenges on Induction of Broadly Neutralizing Antibodies for Optimization of HIV Vaccines Development and Vectored Immunoprophylaxis
... simple vaccine modalities are quite efficient in priming, more complex vectors such as poxviruses and adeno- viruses have been excellent in boosting ...cessful HIV vaccine trial till ...in HIV ...
5
journal.ppat.1000298.PDF
... an HIV vaccine? It has been argued that effective vaccines, such as live attenuated vaccines, are able to provide effective protection because they stimulate ...
12
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap
... Grttn as a polyprotein had relatively low immunogenicity compared to Env, with minimal responses to Nef and no re- sponses to Tat. Env T-cell responses predominated in our study, a result which has also been reported in ...
11
HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine
... infant HIV-1 acquisition, such as a pediatric HIV ...few HIV vaccine trials have included pediatric ...analyzed vaccine-elicited antibody responses in HIV-exposed ...
14
Recombinant Lactobacillus as a Vaccine Vector for HIV
... immunogenic HIV vaccine. This includes production of HIV subunit peptide vaccines (Baier G et al , 1995), DNA vaccines (Barouch DH, 2000), recombinant viral vaccine vectors including modified ...
100
Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses
... Results: Seventy-nine patients were included, 48 patients (60.7%) serconverted. Thirty-nine patients (49.3%) received 10 µg vaccine dose, 24 patients (61.5%) seroconverted. Forty patients (50.7%) received 40 µg ...
5